Levetiracetam 1000 mg Under Fasting Conditions

Summary

THe objective of this study is to compare the rate and extent of absorption of an investigational formulation of levetiracetam 1000 mg tablet to an equivalent oral dose of the commercially available reference product under fasting conditions.

Timeline

Start

2007-01

Primary completion

2007-01

Completion

2007-01

Outcome

Met primary endpoint

registry analysis (unspecified test); Levetiracetam vs Keppra®; Ratio of Geometric Means 96.7 (90% CI 92.4 to 101) NCT00859521 ↗

registry analysis (unspecified test); Levetiracetam vs Keppra®; Ratio of Geometric Means 98.4 (90% CI 96.9 to 100) NCT00859521 ↗

registry analysis (unspecified test); Levetiracetam vs Keppra®; Ratio of Geometric Means 98.8 (90% CI 97.2 to 100) NCT00859521 ↗

Drugs

Evaluation	Drug	Modality	Dose	Route
Subject	Levetiracetam	Other / unclassified	1000 mg	Oral

Indications

No indication recorded.